A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Inclusion Criteria:

Donor:

Donor eligibility will be determined according to applicable federal, state and local regulations and institutional standards
18-65 years of age
6/6 HLA-matched sibling
Fulfill individual Transplant Center criteria to serve as a mobilized blood cell donor
Serum creatinine <2.0mg/dl

Recipient:

18 to 65 years of age
6/6 HLA antigen matched sibling willing to donate PBSC for transplant
Fulfill individual Transplant Center Criteria for transplant

One of the following diagnoses:

Acute myelogenous leukemia (AML) in 1st remission or beyond with <5% marrow blasts and no circulating blasts. Marrow must be done within 30 days of the start of transplant conditioning regimen in alignment with other pre-transplant assessments.
Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with <5% marrow blasts and no circulating blasts
Myelodysplastic syndrome, either intermediate-1,2, or high risk by International Prognostic Scoring System or transfusion dependent
Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase inhibitor based therapy
Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete remission, partial remission, or in relapse (but with at least stable disease after most recent therapy)
Chronic lymphocytic leukemia (CLL), relapsing after at least one prior regimen, or in remission with 17p deletion
Serum creatinine must be <2.0mg/dl
Total bilirubin and aspartate aminotransferase (AST) <3x normal
Infectious disease marker (IDM) monitoring will be performed per institutional standards
Karnofsky performance status of 70% or greater.
Patients who have undergone a prior autologous transplantation are eligible for a reduced intensity transplant only

Exclusion Criteria:

Donor:

Donor unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
Donor already enrolled on another investigational agent study
Pregnant or breast feeding females, or females not willing or able to use adequate contraception if sexually active

Recipient:

Patient unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
Patients with active, uncontrolled infection at the time of the transplant preparative regimen
Pregnant or breast feeding females, or females not willing or able to use adequate contraception if sexually active
Patients with a history of previous central nervous system (CNS) tumor involvement showing active symptoms or signs along with documented disease on lumbar puncture and MRI of the brain within 30 days of start of conditioning
A condition, which, in the opinion of the clinical investigator, would interfere with the evaluation of primary and secondary endpoints.